Repatha (Evolocumab) Cost vs. Alternatives: Comparing PCSK9 Inhibitors and Other LDL-Lowering Options

How Evolocumab (Repatha) Works

Evolocumab is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating enzyme the liver produces to tag LDL receptors for degradation. By blocking PCSK9, evolocumab allows more LDL receptors to recycle back to the hepatocyte surface, pulling additional LDL-C particles out of the bloodstream. The result is a rapid, pronounced drop in circulating LDL-C that begins within days of the first injection.

Mechanism in Clinical Terms

PCSK9 normally binds to the epidermal growth factor-like repeat A domain on the LDL receptor. Once that binding occurs, the receptor-PCSK9 complex is internalized and routed to lysosomes for destruction rather than recycled. Evolocumab intercepts PCSK9 before it reaches the receptor. A single 140 mg subcutaneous dose every two weeks, or 420 mg once monthly, maintains PCSK9 suppression throughout the dosing interval. In the FOURIER trial (N=27,564), this mechanism produced a mean LDL-C reduction of 59% versus placebo when added to background statin therapy 1.

Who Needs a PCSK9 Inhibitor

The 2018 AHA/ACC cholesterol guideline identifies PCSK9 inhibitors as reasonable add-on therapy for patients with clinical atherosclerotic cardiovascular disease (ASCVD) whose LDL-C remains ≥70 mg/dL on maximally tolerated statin plus ezetimibe 2. Patients with heterozygous familial hypercholesterolemia (HeFH) who cannot reach target LDL-C with oral agents also qualify. The FDA approved evolocumab for both indications in 2015, with a supplemental approval for cardiovascular risk reduction in established ASCVD following FOURIER results 3.

Repatha Pricing: What It Actually Costs

The list price of Repatha dropped roughly 60% in early 2023 when Amgen voluntarily reduced the wholesale acquisition cost (WAC) from approximately $14,100 to about $6,168 per year. That headline number still overstates what most insured patients pay.

Wholesale vs. Net Price

Pharmacy benefit managers negotiate rebates that push net prices well below WAC. ICER's 2023 reassessment estimated net commercial prices for PCSK9 inhibitors at $3,400 to $4,500 per year, a range that aligns with value-based price benchmarks for the observed cardiovascular benefit 4. Medicare Part D beneficiaries may face different cost-sharing structures, though the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) limits catastrophic exposure.

Copay Assistance Programs

Amgen's Repatha Ready copay card covers eligible commercially insured patients for as little as $5 per month. Patients without commercial insurance or those on government plans do not qualify for manufacturer copay cards under federal anti-kickback rules. For uninsured patients, Amgen's patient assistance program may provide Repatha at no cost if income falls below 300% of the federal poverty level.

Head-to-Head: Repatha vs. Praluent (Alirocumab)

Alirocumab (Praluent, Regeneron/Sanofi) is the other injectable PCSK9 inhibitor on the U.S. Market. The two drugs share the same target and a similar side-effect profile, but their outcomes trials enrolled different populations.

Efficacy Comparison

FOURIER enrolled patients with stable ASCVD; ODYSSEY OUTCOMES (N=18,924) enrolled patients within 1 to 12 months of an acute coronary syndrome event 5. FOURIER showed a 15% relative risk reduction in the primary composite of cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization at a median follow-up of 2.2 years 1. ODYSSEY OUTCOMES demonstrated a 15% relative reduction in major adverse cardiovascular events and, in a prespecified analysis, a reduction in all-cause mortality among patients with baseline LDL-C ≥100 mg/dL 5.

Cost Comparison

Praluent's WAC sits in a comparable range following its own list-price reductions. Formulary placement varies by insurer. Some plans prefer one agent based on negotiated rebates rather than clinical differentiation. Patients should check their plan's preferred PCSK9 inhibitor before starting therapy, because switching from a non-preferred to a preferred agent can reduce monthly copays from $150+ to under $25.

Repatha vs. Inclisiran (Leqvio): The Newer PCSK9 Option

Inclisiran is a small interfering RNA (siRNA) that silences hepatic PCSK9 messenger RNA rather than neutralizing the circulating protein. The FDA approved inclisiran in December 2021 for HeFH and clinical ASCVD.

Dosing Convenience

Inclisiran requires only two injections per year after an initial dose and a 3-month booster, administered in a healthcare provider's office. Evolocumab requires patient self-injection every 2 or 4 weeks. For patients who struggle with injection adherence, the twice-yearly schedule may be a practical advantage.

Efficacy and Outcomes Data

The ORION-10 and ORION-11 trials (combined N=3,178) showed LDL-C reductions of approximately 50-52% versus placebo at day 510, numerically similar to but slightly below the 59% reduction seen with evolocumab in FOURIER 6. The ORION-4 cardiovascular outcomes trial (N=15,516) reported a 11% reduction in major vascular events at a median follow-up of ~5 years, with prespecified analyses showing stronger effects in later years of follow-up 7.

Cost

Inclisiran's WAC is approximately $3,250 per injection ($6,500/year for maintenance dosing). Because it is administered in-office, it may be billed under a patient's medical benefit (Part B for Medicare) rather than the pharmacy benefit, which changes cost-sharing dynamics. Some patients find Part B coverage more favorable; others face higher coinsurance.

Oral Alternatives: Ezetimibe and Bempedoic Acid

Not every patient with residual LDL-C elevation needs an injectable. Two oral agents offer moderate additional LDL lowering at a fraction of the cost.

Ezetimibe

Generic ezetimibe costs $15 to $40 per month at most retail pharmacies. It inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the intestinal brush border, reducing cholesterol absorption by about 50%. Added to a statin, ezetimibe lowers LDL-C by an additional 18-25%. The IMPROVE-IT trial (N=18,144) showed that simvastatin plus ezetimibe reduced the composite cardiovascular endpoint by 6.4% relative to simvastatin alone over 7 years (HR 0.936, 95% CI 0.89-0.99) 8. The absolute benefit was modest, concentrated in patients with diabetes.

Bempedoic Acid

Bempedoic acid (Nexletol, Esperion) inhibits ATP-citrate lyase upstream of HMG-CoA reductase in the cholesterol synthesis pathway. It is a prodrug activated only in hepatocytes, which means it does not cause skeletal muscle side effects. The CLEAR Outcomes trial (N=13,970) enrolled statin-intolerant patients and showed a 13% reduction in MACE over 3.4 years with bempedoic acid versus placebo 9. LDL-C dropped approximately 21% from baseline. At a WAC of about $4,800/year, bempedoic acid costs less than PCSK9 inhibitors but delivers substantially less LDL-C reduction. It may serve as a bridge for patients who are statin-intolerant but do not yet qualify for or cannot access a PCSK9-targeted therapy.

High-Intensity Statins: The Cost-Effectiveness Benchmark

Generic rosuvastatin (20-40 mg) and atorvastatin (40-80 mg) remain the most cost-effective LDL-lowering agents available. A 90-day supply of generic rosuvastatin 20 mg runs under $15 at many pharmacies.

Where Statins Fall Short

High-intensity statins lower LDL-C by 50-55% as monotherapy, a ceiling that leaves many FH and high-risk ASCVD patients above target. The 2022 EAS consensus statement on FH management estimates that 80% of HeFH patients will not reach an LDL-C goal of <70 mg/dL on statin plus ezetimibe alone, making PCSK9 inhibitors a clinical necessity for this population 10.

Statin Intolerance

True statin myopathy confirmed by rechallenge affects an estimated 5-7% of patients, per a 2022 Lancet meta-analysis that separated nocebo-driven symptoms from pharmacologically mediated muscle effects 11. For genuinely intolerant patients, bempedoic acid plus ezetimibe (available as the fixed-dose combination Nexlizet) or a PCSK9-targeted agent become the primary options.

Comparative Cost-Effectiveness: What the Data Show

ICER's 2023 updated evidence report concluded that at current net prices, PCSK9 inhibitors meet conventional cost-effectiveness thresholds ($50,000-$150,000 per QALY) for patients with established ASCVD and LDL-C ≥100 mg/dL despite maximally tolerated statin therapy 4. This represents a major shift from the initial 2017 ICER assessment, which found the original list price far exceeded value-based benchmarks.

Tier Placement and Prior Authorization

Most commercial and Medicare Part D plans cover at least one PCSK9 inhibitor but require prior authorization documenting: a diagnosis of HeFH or clinical ASCVD, current use of a maximally tolerated statin, LDL-C lab values above goal, and in some cases a trial of ezetimibe. Step-therapy requirements add 30 to 90 days before approval, during which LDL-C remains uncontrolled. Prescribers can sometimes expedite authorization by submitting peer-to-peer reviews with plan medical directors.

Choosing by Value

For a patient with ASCVD, LDL-C of 95 mg/dL on rosuvastatin 40 mg plus ezetimibe, and commercial insurance with a Repatha copay card, the out-of-pocket cost of adding evolocumab may be $5 to $25 per month, with an expected additional LDL-C reduction of 55-60%. That profile is difficult to match with any oral alternative. For a different patient, one with borderline LDL-C elevation and no ASCVD, adding bempedoic acid at $100 to $150/month (after insurance) may be the more proportionate choice.

Safety Profile Across Alternatives

PCSK9 Inhibitors

Injection-site reactions occur in approximately 3-5% of patients on evolocumab or alirocumab. Nasopharyngitis and upper respiratory symptoms appear at slightly higher rates than placebo in pooled trial data. Neurocognitive endpoints were formally assessed in the EBBINGHAUS substudy of FOURIER (N=1,974), which found no difference in cognitive function between evolocumab and placebo over 19 months of follow-up 12.

Inclisiran

The ORION trials reported injection-site reactions in about 5% of patients, mostly mild. Because inclisiran acts intracellularly, there is a theoretical concern about hepatic RNA accumulation with long-term use, though transaminase elevations were not significantly increased versus placebo through 18 months 6.

Oral Agents

Ezetimibe has a 20-year safety track record with minimal serious adverse events. Bempedoic acid carries a signal for hyperuricemia and gout (observed in 1.4% vs. 0.4% placebo in CLEAR Outcomes) and modest increases in serum creatinine 9.

Side-by-Side Summary Table

| Agent | LDL-C Reduction (added to statin) | CV Outcomes Data | Approximate Annual WAC | Route / Frequency | |---|---|---|---|---| | Evolocumab (Repatha) | 55-65% | FOURIER: 15% MACE reduction | ~$6,168 | SC q2wk or q4wk (self-inject) | | Alirocumab (Praluent) | 50-63% | ODYSSEY: 15% MACE reduction | ~$5,850-$6,200 | SC q2wk or q4wk (self-inject) | | Inclisiran (Leqvio) | 50-52% | ORION-4: 11% MVE reduction | ~$6,500 | SC q6mo (in-office) | | Bempedoic acid (Nexletol) | 15-18% | CLEAR: 13% MACE reduction (statin-intolerant) | ~$4,800 | Oral daily | | Ezetimibe (generic) | 18-25% | IMPROVE-IT: 6.4% relative reduction | ~$180-$480 | Oral daily | | Rosuvastatin 40 mg (generic) | 50-55% (monotherapy) | CTT meta-analysis: ~22% per mmol/L LDL reduction | ~$60-$180 | Oral daily |